Full-Time

Senior Medical Science Liaison

Oncology

Eisai

Eisai

Compensation Overview

$165.3k - $216.9k/yr

+ Annual Incentive Plan + Long Term Incentive Plan

Philadelphia, PA, USA + 1 more

More locations: Pittsburgh, PA, USA

In Person

Field-based in PA; requires ~60% travel; home-based office setup required.

Category
Biology & Biotech (1)
Required Skills
FDA Regulations
Pharmacology
Requirements
  • An advanced, terminal Doctorate level (Doctor of Medicine, Doctor of Philosophy, Doctor of Pharmacy, Doctor of Public Health, or Doctor of Education) degree in medical or health sciences.
  • For Medical Science Liaison (MSL), zero to three years of experience in the pharmaceutical or biotechnology industry, a clinical pharmacist role, or research, or related experience in a scientific or clinical setting, preferably as an MSL.
  • For Senior Medical Science Liaison (Sr. MSL), a minimum of three years of MSL experience in Oncology or Hematology.
  • Strong broad-based scientific and pharmaceutical knowledge.
  • Knowledge of treatment guidelines, clinical research processes, FDA regulations and Office of Inspector General guidelines.
  • Knowledge and experience within Eisai's desired therapeutic areas and the ability to communicate confidently and accurately across multiple disease states.
  • Established relationships with key opinion leaders and knowledge of institutions in therapeutic areas of interest.
  • Ability to travel frequently, approximately sixty percent of the time, including air travel and potential overnight and weekend travel.
  • Valid driver's license.
  • This is a field-based position requiring a home-based office setup.
  • Demonstrated ability to work independently and not require close supervision while adhering to Medical Affairs strategic direction.
  • Excellent presentation and teaching skills; strong written and verbal communication.
Responsibilities
  • Act as the primary clinical/scientific resource to Healthcare Providers in the territory for information pertaining to disease state and Eisai's product(s) to ensure awareness and understanding.
  • Serve as a conduit for accurate and updated clinical, scientific and medical information between Key Opinion Leaders and Eisai Medical Affairs and development groups.
  • Establish, foster, cultivate and maintain peer relationships with Key Opinion Leaders in therapeutic areas of interest.
  • Share knowledge and participate in scientific exchanges and interactions with identified KOLs.
  • Present clinical, scientific and economic data on Eisai’s products and relevant therapeutic areas to population-based decision-makers, as requested.
  • Support assigned professional congresses in accordance with MSL plan and lead congress coverage efforts as required.
  • Identify and report key scientific, clinical and research insights from KOLs to Medical Affairs.
  • Develop, implement and present management plans to support Medical Affairs strategic direction for assigned territory.
  • Maintain and demonstrate thorough and up-to-date knowledge of disease state, study methodology, clinical information, and product data.
  • Demonstrate full knowledge of and ability to execute on approved medical platforms/strategies and MSL initiatives.
  • Serve as technical/scientific subject matter resource to Eisai commercial personnel if requested.
  • Teach, coach and mentor new or less experienced MSLs; assist with supervision/performance evaluation; assume responsibility for special projects.
  • Facilitate review and follow up of submitted Investigator-Initiated Studies and assist with Eisai sponsored trials.
  • Serve as primary contact to external investigators who submit IISs; may involve site selection recommendations and scientific expertise for company-sponsored post-marketing studies.
  • Lead field medical efforts in support of Eisai’s collaboration and interactions with professional organizations/societies and advocacy groups.
Desired Qualifications
  • Clinical trial development and drug launch experience is strongly preferred.
  • Experience teaching, coaching and mentoring less experienced Medical Science Liaison colleagues.
  • Experience leading and participating in cross-functional projects.

Company Size

N/A

Company Stage

N/A

Total Funding

N/A

Headquarters

N/A

Founded

N/A

Simplify Jobs

Simplify's Take

What believers are saying

  • EMA validates taletrectinib MAA, targeting 2% ROS1+ NSCLC in 400,000 annual EU cases.
  • Lecanemab presents 48-month Clarity AD data and real-world US persistence at AD/PD 2026.
  • Etalanetug advances in Tau NexGen Phase II/III with lecanemab for dominantly inherited AD.

What critics are saying

  • Tazverik discontinues in Japan due to secondary hematologic malignancies from trials.
  • Donanemab captures early AD share with faster subcutaneous adoption before Eisai's May 2026 PDUFA.
  • Etalanetug Phase II Study 202 fails if no cognitive benefit beyond lecanemab by 2028.

What makes Eisai unique

  • Lecanemab targets amyloid-beta protofibrils, approved in 53 countries including US, Japan, EU.
  • Etalanetug reduces CSF eMTBR-tau243 by 89% at 9 months in Phase Ib/II Alzheimer's trials.
  • Taletrectinib licensed from Nuvation Bio for ROS1+ NSCLC post-US, China, Japan approvals.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Mental Health Support

Conference Attendance Budget

Professional Development Budget

Stock Options

Company Equity

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Remote Work Options

Home Office Stipend

Phone/Internet Stipend

Company News

PR Newswire
Mar 26th, 2026
Eisai and Nuvation Bio submit MAA for taletrectinib in ROS1-positive NSCLC to EMA

Eisai and Nuvation Bio announced that the European Medicines Agency has validated their Marketing Authorisation Application for taletrectinib to treat advanced ROS1-positive non-small cell lung cancer. The filing will follow a standard review timeline and has been accepted for full approval consideration. Taletrectinib is already approved in the US, China and Japan for this indication. Additional filings are planned for the UK, Canada and other regions within Eisai's licensed territories following the January 2026 licensing and collaboration agreement between the companies. The application is based on data from two pivotal Phase 2 studies, TRUST-I and TRUST-II. Approximately 2% of NSCLC patients have ROS1-positive disease. Nearly 400,000 people are diagnosed with lung cancer in Europe annually, with NSCLC accounting for 80% of cases.

Japan Industry News
Mar 19th, 2026
Eisai to discontinue Tazverik sales in Japan amid safety concerns.

Eisai to discontinue Tazverik sales in Japan amid safety concerns. Eisai Co., Ltd. has announced plans to discontinue the administration and sales of its anticancer agent Tazverik (tazemetostat hydrobromide) in Japan. This decision follows the voluntary withdrawal of the product in the United States and other countries due to safety concerns. The company has been reviewing safety data from clinical trials and postmarketing reports, which revealed multiple cases of secondary hematologic malignancies associated with both combination and monotherapy treatments using tazemetostat. After a comprehensive evaluation, Eisai concluded that the risk of these malignancies necessitates discontinuing the drug in Japan, even under approved conditions of use. Eisai is currently communicating with medical institutions in Japan to ensure the immediate discontinuation of Tazverik for patients currently receiving it and to prevent the initiation of new treatments. The company emphasized its commitment to providing timely and appropriate information to healthcare professionals to minimize confusion or disruption. The SYMPHONY-1 trial, a phase 1b/3 study, is evaluating the efficacy of adding tazemetostat to the standard second-line treatment of rituximab plus lenalidomide (R2 therapy) in patients with relapsed or refractory follicular lymphoma. This trial is being conducted under Ipsen's leadership as a confirmatory trial for the accelerated approval of Tazverik in the United States and China, involving 229 sites across 15 countries. However, no sites in Japan are participating. Tazemetostat, a first-in-class oral small molecule inhibitor targeting EZH2, was developed under a collaboration between Eisai and Epizyme, Inc., an Ipsen company. Eisai holds exclusive development and commercialization rights for the agent in Japan.

Japan Industry News
Mar 17th, 2026
Eisai opens global IT hub in India to boost operations.

Eisai opens global IT hub in India to boost operations. Eisai Co., Ltd. has inaugurated the Eisai Global Capability Centre (EGCC) in Visakhapatnam, India, marking a significant step in the company's long-term IT strategy. The new center, located within the Eisai Knowledge Centre, aims to serve as the company's information technology hub. The opening ceremony featured notable attendees, including Muneo Takahashi, Consul General of Japan in Chennai, Keisuke Naito, Eisai's COO and Chief Growth Officer, Yumiko Aoyagi, First Secretary at the Embassy of Japan in India, and Vijaya Krishnan, IAS District Director of Anakapalli. The establishment of the EGCC is a core initiative of Eisai Group's strategy to integrate external expertise and cutting-edge technologies. The center will insource the design and operation of internal IT services, providing standardized, high-quality services in a secure environment to support Eisai's global operations. Initially, the EGCC will focus on standardizing global IT infrastructure operations. Its scope will gradually expand to include cybersecurity, data and analytics, and operational applications, adapting to business needs. Since 2009, the Eisai Knowledge Centre in Andhra Pradesh has been a core operational hub for global production and process research. The region is currently focused on establishing a "New IT City," aiming to create 300,000 IT jobs by attracting data centers and AI hubs. By establishing the EGCC in this location, Eisai plans to recruit and nurture global IT talent aligned with its "human health care" concept. The company aims to contribute to the local IT ecosystem and economic prosperity through long-term employment and career development opportunities.

Clival Private Limited
Mar 11th, 2026
Eisai to Present New Lecanemab Data at AD/PD 2026 Conference

Eisai to present new lecanemab data at AD/PD 2026 conference. Eisai Co., Ltd. will present new research on Lecanemab, its therapy for Alzheimer's disease, at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders 2026. The conference will take place March 17-21, 2026, in Copenhagen and online. Eisai plans to present six research updates, including three oral presentations and several poster sessions, highlighting real-world data and long-term outcomes associated with lecanemab. Focus on real-world outcomes and long-term data. The upcoming presentations will emphasize real-world clinical evidence and long-term treatment outcomes for patients receiving lecanemab. Key oral presentations will cover: * Safety and effectiveness of lecanemab in APOE4 homozygous patients based on data from the LEADER real-world study * Long-term treatment persistence and patient characteristics among individuals using lecanemab in routine clinical practice in the United States * A genome-wide association study identifying genetic variants linked to cognitive decline in Alzheimer's disease These findings aim to deepen understanding of how anti-amyloid therapies perform outside controlled clinical trials. Additional poster presentations. Four additional studies will be presented as posters at the conference. Highlights include: * 48-month results from the Clarity AD open-label extension study, focusing on patients who are APOE ε4 non-carriers and heterozygotes * Research examining how lecanemab reduces amyloid-beta protofibrils and how these reductions correlate with biomarkers linked to neuronal and synaptic health * Development of a fully automated plasma pTau205 immunoassay, created in collaboration with Sysmex Corporation Poster sessions will be available for viewing March 17-19 (CET). Industry symposium on early Alzheimer's intervention. Eisai will also host a sponsored symposium titled: "Continue Life Their Way: Early Intervention in Alzheimer's Disease." The session will feature global experts discussing several key topics: * Why early intervention is critical in Alzheimer's disease * Long-term evidence supporting continued treatment in early disease stages * How real-world data can guide clinical decision-making The symposium aims to highlight the importance of recognizing Alzheimer's disease as a chronic condition requiring multidisciplinary care. About lecanemab (LEQEMBI). Lecanemab is a humanized monoclonal antibody designed to target amyloid-beta protofibrils, toxic protein aggregates believed to play a key role in Alzheimer's disease progression. By targeting these aggregates, the therapy aims to: * Reduce amyloid buildup in the brain * Limit neuronal damage * Slow cognitive decline The therapy emerged from a long-standing research collaboration between Eisai Co., Ltd. and BioArctic AB. Global approvals and regulatory progress. Lecanemab has already received approval in more than 50 countries and regions, including: * United States * Japan * China * European Union * South Korea * Saudi Arabia Recent regulatory developments include: * U.S. FDA approval of subcutaneous maintenance dosing (August 2025) * Priority Review for a supplemental Biologics License Application, with a decision expected May 24, 2026 * Ongoing regulatory review of a subcutaneous formulation in multiple countries Ongoing clinical research. Several major clinical trials continue to investigate lecanemab's potential. One of the most notable is the AHEAD 3-45 trial, which focuses on individuals with preclinical Alzheimer's disease who have elevated amyloid levels but no cognitive symptoms. The trial is conducted through a public-private partnership involving: * Alzheimer's Clinical Trial Consortium * National Institute on Aging * Eisai Co., Ltd. * Biogen Inc. Another ongoing program is the Tau NexGen study, which investigates treatments for dominantly inherited Alzheimer's disease. Advancing Alzheimer's treatment strategies. The upcoming presentations at AD/PD 2026 reflect growing interest in real-world evidence, biomarker development, and long-term treatment outcomes for Alzheimer's disease therapies. As research continues, therapies like lecanemab may help refine early intervention strategies, potentially improving long-term outcomes for patients living with this progressive neurodegenerative condition. Optimize your trial insights with Clival Database. Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you. Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets. With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost. To add value, Clival further break down its analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible. Elevate your trial success rate with the cutting-edge insights from Clival database.

Eisai
Mar 10th, 2026
Eisai to present the latest data on long-term, real-world treatment with lecanemab at the AD/PD(TM) 2026 annual meeting.

Eisai to present the latest data on long-term, real-world treatment with lecanemab at the AD/PD(TM) 2026 annual meeting. Mar 10, 2026 TOKYO, March 10, 2026 /PRNewswire/ - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI(R), Eisai's anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD), at the 20th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD(TM) 2026) from March 17-21, in Copenhagen, Denmark, and online. The lecanemab data and additional research findings from Eisai's AD portfolio will be featured in six presentations, including three oral presentations. Eisai will host an industry-sponsored symposium. Oral and Poster Presentations Oral presentations will include the latest findings from a United States (U.S.) real-world long-term treatment persistence study, and efficacy and safety outcomes in apolipoprotein E ε4 (ApoEε4) homozygous carriers in a U.S. multicenter real-world study. In addition, four-year data from the Clarity AD Open-Label Extension trial in ApoEε4 non-carriers and heterozygotes, and a genome-wide association study on novel genetic variants associated with cognitive decline in AD will be presented as posters. Eisai Symposium - Continue Life Their Way: Early Intervention in Alzheimer's Disease Eisai is sponsoring a symposium featuring four leading global experts in the field of AD, on the topics of why early intervention matters, continuing early AD treatment and real-world outcomes. The symposium aims to enhance understanding of the value of early and continued anti-amyloid treatment in early AD by exploring how real-world evidence can support confident patient assessment in clinical practice, and how to recognize AD as a chronic condition that requires a multidisciplinary approach to care. AD/PD(TM) 2026 Presentations Relating to Eisai's Key Compounds and Research | Oral Presentations | | Asset / Topic, Session, Presentation Time (Central Europe Time: CET) | Presentation Title | | Lecanemab Real-World Outcomes and Mechanistic Insights in Anti-Amyloid Treatment Friday, March 20, 16:50-17:05 | Safety and Effectiveness of Lecanemab in Patients who are APOE4 Homozygous (E4/E4): Sub-Analysis from a US Multicenter, Retrospective Real-World Study (LEADER) | | Lecanemab Real-World Outcomes and Mechanistic Insights in Anti-Amyloid Treatment Friday, March 20, 17:05-17:20 | Long-Term Persistence and Patient Characteristics for Lecanemab in Real-World Use in the United States | | Biomarkers and Imaging Genomic Landscapes in AD, PD and Dementia Wednesday, March 18, 16:15-16:30 | Genome-wide Association Study in Mission AD Clinical Trials Identifies Novel Genetic Variants Associated with Cognitive Decline in Alzheimer's Disease | | Poster Presentations | | Asset / Project | Presentation Title | | Lecanemab | Lecanemab for Early Alzheimer's Disease: 48-Month Results for APOE E4 Non-Carriers and Heterozygotes from the Clarity AD Open-Label Extension | | Lecanemab | Reduction of Brain Aβ Protofibrils by Lecanemab Correlates with CSF pTau217 and Neuronal/Synaptic Biomarkers in APP[NL-G-F] /MAPT Double Knock-in Mice | | Biomarkers and Imaging | Development of a Fully Automated Plasma pTau205 Immunoassay Demonstrating High Concordance with an Immunoprecipitation Mass Spectrometry Assay (Collaboration with Sysmex) | Poster viewing time is from 7:30 on Tuesday, March 17 to 11:10 on Thursday, March 19 (CET). Eisai-Sponsored Symposium: Industry Symposium 05 Wednesday, March 18, 11:10- 12:50 (CET) | Symposium Title: Continue Life Their Way: Early Intervention in Alzheimer's Disease | | Identity and independence: Why early intervention matters | | Extending the evidence over time: Continuing early AD treatment | | Extending the evidence into clinical practice: Real-world outcomes | Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. [Notes to editors] * About lecanemab (generic name, brand name: LEQEMBI(R) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab has been approved in 53 countries and regions including Japan, the United States, China, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in 7 countries including the U.S., China, the UK, and others, and applications have been filed in 10 countries and regions. The U.S. FDA approved Eisai's Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. A Supplemental Biologics License Application (sBLA) for initiation treatment was accepted in January 2026. The sBLA has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of May 24, 2026. In November 2025, an application for a subcutaneous injectable formulation in Japan was submitted. In January 2026, the Biologics License Application (BLA) for the subcutaneous formulation was accepted in China. In December 2025, Lecanemab (IV) has been included in the "Commercial Insurance Innovative Drug List", recently introduced by the National Healthcare Security Administration (NHSA) of China. Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy. * About Protofibrils Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of soluble Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.[1] Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.[2] * About the Collaboration between Eisai and Biogen for AD Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority. * About the Collaboration between Eisai and BioArctic for AD Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015. References 1. Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12: 3451. doi:10.1038/s41467-021-23507-z. 2. Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. SOURCE Eisai Inc. For further information: Public Relations Department, Eisai Co., Ltd., +81-(0)3-3817-5120; Eisai Europe, Ltd., (Europe, Australia, New Zealand and Russia), EMEA Communications Department, +44 (0) 7739-600-678, [email protected]; Eisai, Inc. (U.S.), Julie Edelman, +1-862-213-5915, Julie [email protected]